Affordable Access

deepdyve-link
Publisher Website

Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.

Authors
  • Larson, Kajal B1
  • Cressey, Tim R2
  • Yogev, Ram3
  • Wiznia, Andrew4
  • Hazra, Rohan5
  • Jean-Philippe, Patrick6
  • Graham, Bobbie7
  • Gonzalez, Amy7
  • Britto, Paula8
  • Carey, Vincent J8
  • Acosta, Edward P1
  • 1 University of Alabama at Birmingham.
  • 2 Program for HIV Prevention and Treatment, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand Harvard School of Public Health, Boston, Massachusetts. , (Thailand)
  • 3 Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • 4 Jacobi Medical Center, Bronx, New York.
  • 5 National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Maternal and Pediatric Infectious Disease Branch, Bethesda, Maryland.
  • 6 HJF-DAIDS, a Division of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
  • 7 Frontier Science & Technology, Amherst, New York.
  • 8 Harvard School of Public Health, Boston, Massachusetts.
Type
Published Article
Journal
Journal of the Pediatric Infectious Diseases Society
Publisher
Oxford University Press
Publication Date
Jun 01, 2016
Volume
5
Issue
2
Pages
131–137
Identifiers
DOI: 10.1093/jpids/piu142
PMID: 27199469
Source
Medline
Keywords
License
Unknown

Abstract

The results suggest that DRV/r QD with ETR 400 mg QD or 200 mg BID is appropriate and support further evaluation of the safety and efficacy of the once-daily regimen in older children, adolescents, and young adults.

Report this publication

Statistics

Seen <100 times